U.K. snubs Avastin; Pfizer must pay opposing lawyers $180M; Valeant closes Russian deal;

@FiercePharma: Genzyme's $176K Kynamro price undercuts its $250K-plus rival. But rivalry in orphan drugs isn't the usual. Article | Follow @FiercePharma

@EricPFierce: Medicare refiguring how it will pay for dialysis drugs. It is part of the new payer world. More | Follow @EricPFierce

> The U.K. cost watchdog NICE has recommended against use of Roche's ($RHHBY) cancer drug Avastin for treating advanced ovarian cancer that has returned after chemotherapy. Release

> A consent decree on Boehringer Ingelheim's Ben Venue Laboratories' Bedford, OH, plant has been approved, putting strict limits on production there. Release

> New rates from Medicare for dialysis drugs will be put in place next year. Story

> Bristol-Myers Squibb ($BMY) reportedly wants to cash in on high demand for consumer lines by selling some of its product lines in Mexico and Brazil. Story  

> Valeant Pharmaceuticals ($VRX) has completed its acquisition of Natur Produkt for about $163 million. Release

> Actavis has lost a patent case over its generic version of Pfizer's ($PFE) Rapamune used in organ transplants. Release

> An Arkansas judge has ordered Johnson & Johnson ($J&J) to pay $181 million in legal fees to lawyers who beat it in a case over marketing of its antipsychotic drug Risperdal. Story

> China's Luqa Pharmaceuticals says it is launching in China Strataderm Gel for treating scars. Release

Medical Device News

 @FierceMedDev: New special report: Top diagnostics VC investments of 2012. More | Follow @FierceMedDev

 @MarkHFierce: Philips Healthcare had a solid Q4--the overall company, less so. More | Follow @MarkHFierce

 @DamianFierce: Add Smith & Nephew to the list of companies cutting jobs and blaming the 2.3% medical device tax. Report | Follow @DamianFierce

> GE pursues 'corrective action' for more parts used in two infant warmers. Article

> Ivantis hauls in $27M for tiny eye stent. Story

> MITA: CMS should weigh Dx endpoints for beta amyloid PET imaging coverage. Item

Biotech News

 @FierceBiotech: Juventas snaps up business development veteran, more in this week's roundup of hirings and firings in biotech, pharma. More | Follow @FierceBiotech

@JohnCFierce: Odana is one of Merck's top PhIII drugs, and like suvorexant may not sell well against generics. Where's the breakthrough strategy? More | Follow @JohnCFierce

@RyanMFierce: Gilead hungers for more cancer drug deals. But Ariad? Story | Follow @RyanMFierce

> GlaxoSmithKline shoots for combo attack against melanoma in surgery patients. News

> Bayer spotlights positive PhIII data for fat-busting drug. Article

> Merck R&D calls for a time-out on osteo blockbuster hopeful. Report

And Finally... Pfizer ($PFE) finds itself defending a lawsuit that says its popular antidepressant doesn't work. Story

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.